Skip to main content

Advertisement

Table 1 Main outcomes of the BLISS-52 and BLISS-76 trials

From: B-cell activating factor targeted therapy and lupus

  Belimumab 10 mg/kg (%) Belimumab 1 mg/kg (%) Placebo (%)
SRI response rate at 52 weeks (BLISS-52) 58 (P = 0.0006) 51 (P = 0.0129) 44
SRI response rate at 52 weeks (BLISS-76) 43.2 (P = 0.017) 40.6 (P = 0.089) 33.5
SRI response rate at 76 weeks (BLISS-76) 38.5 (P = 0.13) 39.1 (P = 0.11) 32.4
Prednisone dose reduced ≥25%, to ≤7.5% mg/day during weeks 40 to 52 (BLISS-52) 19 (P = 0.0526) 21 (P = 0.025) 12
Prednisone dose reduced ≥25%, to ≤7.5% mg/day during weeks 40 to 52 (BLISS-76) 17.5 (P >0.05) 19.2 (P >0.05) 12.7
  1. SRI, Systemic Lupus Erythematosus Responder Index.